Research programme: MCP-1 receptor antagonists - sanofi-aventis/Millennium

Drug Profile

Research programme: MCP-1 receptor antagonists - sanofi-aventis/Millennium

Alternative Names: CCR2 antagonists research programme - sanofi-aventis/Millennium; MCP-1 receptor antagonists research programme - sanofi-aventis/Millennium; Research programme: CCR2 antagonists - sanofi-aventis/Millennium

Latest Information Update: 19 Jul 2006

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Millennium Pharmaceuticals; sanofi-aventis
  • Class Small molecules
  • Mechanism of Action CCR2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Atherosclerosis; Rheumatoid arthritis

Most Recent Events

  • 19 Jul 2006 No development reported - Preclinical for Rheumatoid arthritis in USA (PO)
  • 26 Aug 2004 Aventis has merged with Sanofi-Synthelabo to form Sanofi-Aventis
  • 03 Feb 2004 No development reported - Preclinical for Atherosclerosis in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top